Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545801 | 0.85 | ALDH1A1 (0.39) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL286585 | 0.78 | LMNA (0.50) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL286584 | 0.77 | LMNA (0.49) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL10295030 | 0.77 | MAPT (0.42) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL25033914 | 0.75 | ADORA3 (0.43) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL1566850 | 0.72 | ALDH1A1 (0.44) | SMN1; SMN2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL19475586 | 0.71 | ALDH1A1 (0.59) | SMN1; SMN2KDM4EALDH1A1HSD17B10ALOX15 | |
| SCHEMBL21963082 | 0.71 | NPC1 (0.49) | SMN1; SMN2NPC1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL29047841 | 0.70 | ELANE (0.46) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL18007580 | 0.70 | SMN1; SMN2 (0.71) | SMN1; SMN2RAB9AKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107708690-B | Pyrimidine derivatives as kinase inhibitors and their therapeutic use | 常山凯捷健生物药物研发（河北）有限公司 | 2021-09-14 | — | — | CN | disclosed |
| EP-3261637-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | SMN1; SMN2 1130/4885NPC1 87/4885RAB9A 3470/4885 |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | DCK, TK1, DTYMK | SMN1; SMN2 3004/4885NPC1 2718/4885RAB9A 2628/4885 |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | SMN1; SMN2 3004/4885NPC1 2718/4885RAB9A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.